Trying smaller, more frequent meals
Common Decision Patterns Profile A: Financial Capacity + Health Improvements Recommended path: Chronic treatment with dose reduction to maintenance level Rationale: You have means to sustain treatment and clear medical benefits that would be lost with discontinuation
Common experiences: Occasional mild GI symptoms, stable energy, reduced food noise, feeling normal on medication
Figure 1d shows the weekly changes in oral food intake
But women, who have higher rates of GLP-1 treatment use than men, may at be at heightened risk of bone weakening during menopause, when bone loss naturally accelerates
+Commonly discussed benefits Strong appetite reduction and meal-size control Substantial body-weight and fat-mass changes in research settings Improvements in glycemic markers and insulin sensitivity Potential improvements in liver-fat markers under study Once-weekly cadence convenient research scheduling +Research highlights Retatrutide is in late-stage clinical research for obesity and metabolic disease, with active Phase 3 programs running under names such as TRIUMPH for obesity and TRIUMPH-MASH for fatty-liver disease
